Антиагреганты при сахарном диабете: современные подходы и перспективы профилактики ишемической болезни сердца
Антиагреганты при сахарном диабете: современные подходы и перспективы профилактики ишемической болезни сердца
Новиков В.И., Новиков К.Ю. Антиагреганты при сахарном диабете: современные подходы и перспективы профилактики ишемической болезни сердца. Consilium Medicum. 2018; 20 (4): 16–23. DOI: 10.26442/2075-1753_2018.4.16-23
________________________________________________
Novikov V.I., Novikov K.Yu. Antiplatelet therapy use in diabetes mellitus patients: modern approaches and ischemic heart disease prevention perspectives. Consilium Medicum. 2018; 20 (4): 16–23. DOI: 10.26442/2075-1753_2018.4.16-23
Антиагреганты при сахарном диабете: современные подходы и перспективы профилактики ишемической болезни сердца
Новиков В.И., Новиков К.Ю. Антиагреганты при сахарном диабете: современные подходы и перспективы профилактики ишемической болезни сердца. Consilium Medicum. 2018; 20 (4): 16–23. DOI: 10.26442/2075-1753_2018.4.16-23
________________________________________________
Novikov V.I., Novikov K.Yu. Antiplatelet therapy use in diabetes mellitus patients: modern approaches and ischemic heart disease prevention perspectives. Consilium Medicum. 2018; 20 (4): 16–23. DOI: 10.26442/2075-1753_2018.4.16-23
Сердечно-сосудистые заболевания являются основной причиной смертности больных сахарным диабетом. Антиагрегантная терапия – важнейший компонент терапии и профилактики ишемической болезни сердца, а основной препарат – ацетилсалициловая кислота (АСК). В представленном обзоре изложены современные подходы к первичной и вторичной профилактике коронарных событий у больных сахарным диабетом, данные опубликованных метаанализов эффективности и безопасности различных доз и форм АСК, а также последние отечественные и новые зарубежные клинические рекомендации.
Cardiovascular diseases are the leading cause of patients with diabetes mellitus mortality. Antiplatelet therapy is a crucial component of ischemic heart disease treatment and prevention, acetylsalicylic acid is the main drug of this group. The review presents modern approaches to primary and secondary prevention of unfavorable cardiovascular events in diabetes mellitus patients, meta-analyses results on effectiveness and safety of various doses and forms of acetylsalicylic acid and recent Russian and international clinical guidelines.
1. Gerstein HC: Reduction of cardiovascular events and microvascularcomplications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Med Res Rev 2002; 18 (Suppl. 3): S82–S85.
2. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342 (13): 905–12.
3. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26 (2): 142–8.
4. Маслова О.В., Сунцов Ю.И. Эпидемиология сахарного диабета и микрососудистых осложнений. Сахарный диабет. 2011; 3: 6–11. / Maslova O.V., Suncov Yu.I. Epidemiologiia saharnogo diabeta i mikrososudistyh oslozhnenij. Saharnyi diabet. 2011; 3: 6–11. [in Russian]
5. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011; 108 (Suppl. 3): 3B–24B.
6. Yde´n L, Mellbin L. Glucose perturbations and cardiovascular risk: challenges and opportunities. Diabetes Vasc Dis Res 2012; 9: 170–6.
7. Ingisser R, Cairns C, Christ M et al. Cardiac troponin: a critical review of the case for point-of-care testing in the ED. Am J Emerg Med 2012; 30: 1639–49.
8. Selvin E, Lazo M, Chen Y et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation 2014; 130: 1374–82.
9. Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
10. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93.
11. Del Cañizo Gómez FJ, Moreira Andrés MN. Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus. Med Clin (Barc) 2008; 130: 641–4.
12. Del Cañizo-Gómez FJ, Moreira-Andrés MN. Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines? Diabetes Res Clin Pract 2004; 65: 125–33.
13. Fonseca VA. Risk factors for coronary heart disease in diabetes. Ann Intern Med 2000; 133: 154–6.
14. Ahmed I, Goldstein BJ. Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Mt Sinai J Med 2006; 73: 759–68.
15. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035–8.
16. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care 1998; 21: 1138–45.
17. Badimon L, Badimon JJ, Vilahur G et al. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb 2002; 32: 225–31.
18. Colwell JA. Vascular thrombosis in type II diabetes mellitus. Diabetes 1993; 42: 8–11.
19. Yang F, Ye J, Pomerantz K et al. Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trialsDiabetes Metab Syndr Obes 2013; 6: 247–56.
20. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134–46.
21. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998; 16: 1407–14.
22. Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005; 2: 16–23.
23. Sukhija R, Aronow WS, Kakar P et al. Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol 2006; 98: 279–81.
24. Stratmann B, Tschoepe D. Atherogenesis and atherothrombosis – focus on diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009; 23: 291–303.
25. Kwaan HC. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992; 41 (Suppl. 2): 32–5.
26. Olexa P, Olexová M. Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus. Vnitr Lek 2003; 49: 222–6.
27. Fujii S, Goto D, Zaman T et al. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. J Atheroscler Thromb 1998; 5: 76–81.
28. McBane RD, Hardison RM, Sobel BE. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial). Am J Cardiol 2010; 105: 17–24.
29. Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol 2017; 16: 34.
30. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. Вып. 8. М., 2017. / Algoritmy specializirovannoi medicinskoi pomoshchi bol'nym saharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Yu.Maiorova. Vyp. 8. М., 2017. [in Russian]
31. Schrúor K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis aspirin causes a bleeding tendency that involves inhibition of platelet function and prostaglandin biosynthesis. 1997; 23.
32. Patrono C, Rocca B. Drug Insight: aspirin resistance – fact or fashion? Nat Clin Pract Cardiovasc Med 2007; 4 (1): 42–50.
33. Russo I, Viretto M, Barale C et al. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes 2012; 61: 2913–21.
34. Close SL. Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundam Clin Pharmacol 2012; 26: 19–26.
35. Ajjan RA, Standeven KF, Khanbhai M et al. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 2009; 29 (5): 712–7. DOI: 10.1161/ATVBAHA.109.183707
36. Bailey MA, Aggarwal R, Bridge KI et al. Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. J Thromb Haemost 2015; 13 (5): 795–801. DOI: 10.1111/jth.12872
37. Tehrani S, Antovic A, Mobarrez F et al. High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes. Diabetes Care 2012; 35 (2): 404–8. DOI: 10.2337/dc11-1302
38. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 7 (4): 260–73. DOI: 10.1177/1479164110383723
39. Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med 2016; 23: 579–93.
40. Ryden L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the ESC and developed in collaboration with the EASD. Eur Heart J 2013; 34 (39): 3035–87.
41. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed) 1988; 296 (6618): 320–31.
42. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
43. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81–106.
44. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
45. Tasdemir E, Toptas T, Demir C et al. Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci 2014; 119 (1): 25–31.
46. Snoep JD, Hovens MM, Eikenboom JC et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and metaanalysis. Arch Intern Med 2007; 167: 1593–9.
47. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195–8.
48. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156–64.
49. Frelinger AL 3rd, Furman MI, Linden MD et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1 and cyclooxygenase-2 independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888–96.
50. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103 (Suppl.): 27A–34A.
51. Michelson AD, Cattaneo M, Eikelboom JW et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3:1309–11.
52. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430–5.
53. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006; 97: 38–43.
54. DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the Aspirin-Induced Platelet Effect (ASPECT) study. Diabetes 2007; 56: 3014–9.
55. Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005; 83: 148–58.
56. Davм G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769–74.
57. Watala C, Golanski J, Pluta J et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): its relation to metabolic control. Thromb Res 2004; 113: 101–13.
58. DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated lowdose aspirin in diabetic angiopathy. Blood 1986; 68: 886–91.
59. Capodanno D, Patel A, Dharmashankar K et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 4 (2): 180–7.
60. Dillinger JG, Drissa A, Sideris G et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J 2012; 164 (4): 600.
61. Rocca B, Santilli F, Pitocco D et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10 (7): 1220–30.
62. Fox CS, Golden SH, Anderson C et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015; 38 (9): 1777–803.
63. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313–6.
64. Steering Committee of the Physicians’ Health Study Research Group Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35.
65. Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264–72.
66. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–304.
67. The Medical Research Council’s General Practice Research Framework Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233–41.
68. Hansson L, Zanchetti A, Carruthers SG et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
69. ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268: 1292–300.
70. Ogawa H, Nakayama M, Morimoto T et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial (published corrections appear in JAMA 2009; 301: 1882 and JAMA 2012; 308: 1861). JAMA 2008; 300: 2134–41.
71. Belch J, MacCuish A, Campbell I et al; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
72. Zhang C, Sun A, Zhang P et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010; 87: 211–8.
73. Younis N, Williams S, Ammori B, Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother 2010; 11: 1459–66.
74. Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med 2011; 26: 1336–44.
75. Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694–701.
76. De Berardis G, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531.
77. Calvin AD, Aggarwal NR, Murad MH et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009; 32: 2300–6.
78. Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 2011; 10: 25.
79. Chew EY, Klein ML, Murphy RP et al. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Arch Ophthalmol 1995; 113: 52–5.
80. Brotons C, Benamouzig R, Filipiak K et al. A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach? Am J Cardiovasc Drugs 2015; 15: 113–33.
81. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Antithrombotic Trialists' Collaboration. BMJ 2002; 324: 71–86.
82. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version, 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 2012 (33): 1635–701.
83. American Diabetes Association. Standards of medical care in diabetes, 2013. Diabetes Care 2013; 36 (Suppl. 1): S11–66.
84. Vandvik PO, Lincoff AM, Gore JM et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e637S–68S.
85. Goldstein LB, Bushnell CD, Adams RJ et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Аssociation/American Stroke Association. Stroke 2011; 42: 517–84.
86. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396–404.
87. Brown N, May JA, Wilcox RG et al. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br J Clin Pharmacol 1999; 48 (1): 57–62.
88. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther 1999; 13: 1109–14.
89. Takahashi S, Mizuno O, Sakaguchi T et al. Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. Adv Ther 2014; 31: 118–29.
90. Guo W, Lu W, Xu Y et al. Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated Aspirin Administration. Clin Drug Investig 2017; 37 (2): 187–93.
91. Hotiezer JW, Silvoso GR, Burks M, Ivey KJ. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 1980; 2: 609–12.
92. Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 304: 136–7.
93. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage. Prevention by enteric coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77–83.
94. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what's the risk? Aliment Pharmacol Ther 2006; 24: 897–908.
95. Rodríguez L, Hernández-Díaz S, Abajo F. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52 (5): 563–71.
96. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 2): 89S–119S.
97. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637–43.
98. Becattini C, Agnelli G, Schenone A et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959–67.
99. Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31–41.
________________________________________________
1. Gerstein HC: Reduction of cardiovascular events and microvascularcomplications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Med Res Rev 2002; 18 (Suppl. 3): S82–S85.
2. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342 (13): 905–12.
3. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26 (2): 142–8.
4. Maslova O.V., Suncov Yu.I. Epidemiologiia saharnogo diabeta i mikrososudistyh oslozhnenij. Saharnyi diabet. 2011; 3: 6–11. [in Russian]
5. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011; 108 (Suppl. 3): 3B–24B.
6. Yde´n L, Mellbin L. Glucose perturbations and cardiovascular risk: challenges and opportunities. Diabetes Vasc Dis Res 2012; 9: 170–6.
7. Ingisser R, Cairns C, Christ M et al. Cardiac troponin: a critical review of the case for point-of-care testing in the ED. Am J Emerg Med 2012; 30: 1639–49.
8. Selvin E, Lazo M, Chen Y et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation 2014; 130: 1374–82.
9. Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
10. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93.
11. Del Cañizo Gómez FJ, Moreira Andrés MN. Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus. Med Clin (Barc) 2008; 130: 641–4.
12. Del Cañizo-Gómez FJ, Moreira-Andrés MN. Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines? Diabetes Res Clin Pract 2004; 65: 125–33.
13. Fonseca VA. Risk factors for coronary heart disease in diabetes. Ann Intern Med 2000; 133: 154–6.
14. Ahmed I, Goldstein BJ. Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Mt Sinai J Med 2006; 73: 759–68.
15. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035–8.
16. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care 1998; 21: 1138–45.
17. Badimon L, Badimon JJ, Vilahur G et al. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb 2002; 32: 225–31.
18. Colwell JA. Vascular thrombosis in type II diabetes mellitus. Diabetes 1993; 42: 8–11.
19. Yang F, Ye J, Pomerantz K et al. Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trialsDiabetes Metab Syndr Obes 2013; 6: 247–56.
20. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134–46.
21. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998; 16: 1407–14.
22. Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005; 2: 16–23.
23. Sukhija R, Aronow WS, Kakar P et al. Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol 2006; 98: 279–81.
24. Stratmann B, Tschoepe D. Atherogenesis and atherothrombosis – focus on diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009; 23: 291–303.
25. Kwaan HC. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992; 41 (Suppl. 2): 32–5.
26. Olexa P, Olexová M. Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus. Vnitr Lek 2003; 49: 222–6.
27. Fujii S, Goto D, Zaman T et al. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. J Atheroscler Thromb 1998; 5: 76–81.
28. McBane RD, Hardison RM, Sobel BE. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial). Am J Cardiol 2010; 105: 17–24.
29. Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol 2017; 16: 34.
30. Algoritmy specializirovannoi medicinskoi pomoshchi bol'nym saharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Yu.Maiorova. Vyp. 8. М., 2017. [in Russian]
31. Schrúor K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis aspirin causes a bleeding tendency that involves inhibition of platelet function and prostaglandin biosynthesis. 1997; 23.
32. Patrono C, Rocca B. Drug Insight: aspirin resistance – fact or fashion? Nat Clin Pract Cardiovasc Med 2007; 4 (1): 42–50.
33. Russo I, Viretto M, Barale C et al. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes 2012; 61: 2913–21.
34. Close SL. Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundam Clin Pharmacol 2012; 26: 19–26.
35. Ajjan RA, Standeven KF, Khanbhai M et al. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 2009; 29 (5): 712–7. DOI: 10.1161/ATVBAHA.109.183707
36. Bailey MA, Aggarwal R, Bridge KI et al. Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. J Thromb Haemost 2015; 13 (5): 795–801. DOI: 10.1111/jth.12872
37. Tehrani S, Antovic A, Mobarrez F et al. High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes. Diabetes Care 2012; 35 (2): 404–8. DOI: 10.2337/dc11-1302
38. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 7 (4): 260–73. DOI: 10.1177/1479164110383723
39. Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med 2016; 23: 579–93.
40. Ryden L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the ESC and developed in collaboration with the EASD. Eur Heart J 2013; 34 (39): 3035–87.
41. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed) 1988; 296 (6618): 320–31.
42. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
43. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81–106.
44. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
45. Tasdemir E, Toptas T, Demir C et al. Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci 2014; 119 (1): 25–31.
46. Snoep JD, Hovens MM, Eikenboom JC et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and metaanalysis. Arch Intern Med 2007; 167: 1593–9.
47. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195–8.
48. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156–64.
49. Frelinger AL 3rd, Furman MI, Linden MD et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1 and cyclooxygenase-2 independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888–96.
50. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103 (Suppl.): 27A–34A.
51. Michelson AD, Cattaneo M, Eikelboom JW et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3:1309–11.
52. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430–5.
53. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006; 97: 38–43.
54. DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the Aspirin-Induced Platelet Effect (ASPECT) study. Diabetes 2007; 56: 3014–9.
55. Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005; 83: 148–58.
56. Davм G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769–74.
57. Watala C, Golanski J, Pluta J et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): its relation to metabolic control. Thromb Res 2004; 113: 101–13.
58. DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated lowdose aspirin in diabetic angiopathy. Blood 1986; 68: 886–91.
59. Capodanno D, Patel A, Dharmashankar K et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 4 (2): 180–7.
60. Dillinger JG, Drissa A, Sideris G et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J 2012; 164 (4): 600.
61. Rocca B, Santilli F, Pitocco D et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10 (7): 1220–30.
62. Fox CS, Golden SH, Anderson C et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015; 38 (9): 1777–803.
63. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313–6.
64. Steering Committee of the Physicians’ Health Study Research Group Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35.
65. Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264–72.
66. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–304.
67. The Medical Research Council’s General Practice Research Framework Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233–41.
68. Hansson L, Zanchetti A, Carruthers SG et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
69. ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268: 1292–300.
70. Ogawa H, Nakayama M, Morimoto T et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial (published corrections appear in JAMA 2009; 301: 1882 and JAMA 2012; 308: 1861). JAMA 2008; 300: 2134–41.
71. Belch J, MacCuish A, Campbell I et al; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
72. Zhang C, Sun A, Zhang P et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010; 87: 211–8.
73. Younis N, Williams S, Ammori B, Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother 2010; 11: 1459–66.
74. Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med 2011; 26: 1336–44.
75. Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694–701.
76. De Berardis G, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531.
77. Calvin AD, Aggarwal NR, Murad MH et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009; 32: 2300–6.
78. Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 2011; 10: 25.
79. Chew EY, Klein ML, Murphy RP et al. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Arch Ophthalmol 1995; 113: 52–5.
80. Brotons C, Benamouzig R, Filipiak K et al. A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach? Am J Cardiovasc Drugs 2015; 15: 113–33.
81. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Antithrombotic Trialists' Collaboration. BMJ 2002; 324: 71–86.
82. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version, 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 2012 (33): 1635–701.
83. American Diabetes Association. Standards of medical care in diabetes, 2013. Diabetes Care 2013; 36 (Suppl. 1): S11–66.
84. Vandvik PO, Lincoff AM, Gore JM et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e637S–68S.
85. Goldstein LB, Bushnell CD, Adams RJ et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Аssociation/American Stroke Association. Stroke 2011; 42: 517–84.
86. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396–404.
87. Brown N, May JA, Wilcox RG et al. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br J Clin Pharmacol 1999; 48 (1): 57–62.
88. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther 1999; 13: 1109–14.
89. Takahashi S, Mizuno O, Sakaguchi T et al. Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. Adv Ther 2014; 31: 118–29.
90. Guo W, Lu W, Xu Y et al. Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated Aspirin Administration. Clin Drug Investig 2017; 37 (2): 187–93.
91. Hotiezer JW, Silvoso GR, Burks M, Ivey KJ. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 1980; 2: 609–12.
92. Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 304: 136–7.
93. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage. Prevention by enteric coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77–83.
94. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what's the risk? Aliment Pharmacol Ther 2006; 24: 897–908.
95. Rodríguez L, Hernández-Díaz S, Abajo F. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52 (5): 563–71.
96. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 2): 89S–119S.
97. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637–43.
98. Becattini C, Agnelli G, Schenone A et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959–67.
99. Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31–41.
Авторы
В.И.Новиков*, К.Ю.Новиков
ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России. 214019, Россия, Смоленск, ул. Крупской, д. 28
*endo@smolgmu.ru
________________________________________________
V.I.Novikov*, K.Yu.Novikov
Smolensk State Medical University of the Ministry of Health of the Russian Federation. 214019, Russian Federation, Smolensk, ul. Krupskoi, d. 28